Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018
26 Luglio 2018 - 1:00PM
Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology
company dedicated to developing cell-based therapeutics to treat
neurological conditions associated with demyelination and cellular
immunotherapies to treat cancer, today announced that it will
release second quarter 2018 financial and operating results on
Thursday, August 9, 2018 after the close of the U.S. financial
markets. The Company will host a conference call and webcast on
August 9, 2018 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the
results and corporate developments.
For both "listen-only" participants and those
participants who wish to take part in the question-and-answer
portion of the call, the dial-in number in the U.S./Canada is
888-599-8686. For international participants outside the
U.S./Canada, the dial-in number is 323-994-2093. For all callers,
refer to Conference ID 7991938. To access the live webcast, go to
http://asteriasbiotherapeutics.com/inv_events_presentations.php.
A replay of the conference call will be
available for one month beginning about two hours after the
conclusion of the live call, by calling toll-free (from
U.S./Canada) 888-203-1112; international callers dial 719-457-0820.
Use the Conference ID 7991938. Additionally, the archived webcast
will be available at
http://asteriasbiotherapeutics.com/inv_events_presentations.php.
About Asterias
Biotherapeutics
Asterias Biotherapeutics, Inc. is a
biotechnology company dedicated to developing cell-based
therapeutics to treat neurological conditions associated with
demyelination and cellular immunotherapies to treat cancer.
Asterias is presently focused on advancing two clinical-stage
programs which have the potential to address areas of very high
unmet medical need in the fields of neurology and oncology.
AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase
1/2a dose escalation clinical trial in spinal cord injury. AST-VAC2
(antigen-presenting allogeneic dendritic cells) is an allogeneic
cancer immunotherapy. The company's research partner, Cancer
Research UK, has commenced a first-in-human clinical trial of
AST-VAC2 in non-small cell lung cancer. AST-VAC1
(antigen-presenting autologous dendritic cells) is an autologous
cancer immunotherapy with promising efficacy and safety data from
an earlier Phase 2 study in Acute Myeloid Leukemia (AML).
Asterias is also sponsoring pre-clinical work in two conditions
with a demyelinating component: Multiple Sclerosis and White Matter
Stroke, and is evaluating other cancer indications where its
immunotherapy platform could provide therapeutic benefit.
Additional information about Asterias can be found at
www.asteriasbiotherapeutics.com.
Contacts:Investor
Relations(510) 456-3892InvestorRelations@asteriasbio.comorEVC
Group, Inc.Michael Polyviou/Todd Kehrli(732)
232-6914mpolyviou@evcgroup.com; tkehrli@evcgroup.com
Grafico Azioni Asterias Biotherapeutics, Inc. (AMEX:AST)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Asterias Biotherapeutics, Inc. (AMEX:AST)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Asterias Biotherapeutics Common Series A (Borsa Americana (AMEX)): 0 articoli recenti
Più Articoli Notizie